News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Moat Ross
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/03/2023 |
4
| Moat Ross (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 38,668 options to buy
@ $10.76, valued at
$416.1k
Granted 6,445 options to buy
@ $0 |
|
| 03/20/2023 |
4
| Moat Ross (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 1,844 shares
@ $9.56, valued at
$17.6k
Paid exercise price by delivering 543 shares
@ $11.46, valued at
$6.2k
Paid exercise price by delivering 1,167 shares
@ $11.12, valued at
$13k
Exercised 994 options to buy
@ $0
Exercised 2,137 options to buy
@ $0 |
|
| 09/06/2022 |
4
| Moat Ross (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 360 shares
@ $9.56, valued at
$3.4k
Paid exercise price by delivering 563 shares
@ $11.44, valued at
$6.4k
Granted 59,460 options to buy
@ $11.97, valued at
$711.7k
Granted 9,908 options to buy
@ $0
Exercised 995 options to buy
@ $0 |
|
| 04/11/2022 |
4
| Moat Ross (CHIEF COMMERCIAL OFFICER) has filed a Form 4 on Kiniksa Pharmaceuticals, Ltd.|
Txns:
| Granted 59,460 options to buy
@ $11.1, valued at
$660k
Granted 9,908 options to buy
@ $0 |
|
| 03/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|